author = {Langbroek, Pepijn. and Polée, Marco. and de Graaf, Hiltje.}, title = {{Escalating erythrocytosis after start of pazopanib-treatment in metastatic renal cell carcinoma}}, journal ={Journal of Current Oncology}, volume ={2}, number ={1}, pages = {26-28}, doi = {10.4103/JCO.JCO_24_18}, year = {2019}, abstract ={Renal cell carcinoma accounts for 2% of adult malignancies in the Netherlands. Metastatic disease is often treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors, such as pazopanib. This treatment is known to cause a slight increase in hemoglobin level during treatment. We present a patient who was diagnosed with metastatic renal cell carcinoma during analyses for erythrocytosis and who developed a further rise in hemoglobin level to 13.2 mmol/L 2 weeks after starting pazopanib treatment. Multiple phlebotomies were necessary before symptoms improved. Preexistent erythrocytosis should be considered as a risk factor for symptomatic erythrocytosis during pazopanib treatment and warrants timely laboratory follow-up and phlebotomies if indicated.}, URL ={http://www.https://journalofcurrentoncology.org//article.asp?issn=2589-8892;year=2019;volume=2;issue=1;spage=26;epage=28;aulast=Langbroek;t=6}, eprint ={http://www.https://journalofcurrentoncology.org//article.asp?issn=2589-8892;year=2019;volume=2;issue=1;spage=26;epage=28;aulast=Langbroek;t=6} }